JP2013511966A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511966A5
JP2013511966A5 JP2012540419A JP2012540419A JP2013511966A5 JP 2013511966 A5 JP2013511966 A5 JP 2013511966A5 JP 2012540419 A JP2012540419 A JP 2012540419A JP 2012540419 A JP2012540419 A JP 2012540419A JP 2013511966 A5 JP2013511966 A5 JP 2013511966A5
Authority
JP
Japan
Prior art keywords
fusion polypeptide
seq
amino acid
domain
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511966A (ja
Filing date
Publication date
Priority claimed from DE102009047243A external-priority patent/DE102009047243A1/de
Application filed filed Critical
Publication of JP2013511966A publication Critical patent/JP2013511966A/ja
Publication of JP2013511966A5 publication Critical patent/JP2013511966A5/ja
Pending legal-status Critical Current

Links

JP2012540419A 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬 Pending JP2013511966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien
DE102009047243.6 2009-11-27
PCT/EP2010/068134 WO2011064257A2 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien

Publications (2)

Publication Number Publication Date
JP2013511966A JP2013511966A (ja) 2013-04-11
JP2013511966A5 true JP2013511966A5 (enExample) 2014-01-09

Family

ID=43589669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540419A Pending JP2013511966A (ja) 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬

Country Status (8)

Country Link
US (2) US9163079B2 (enExample)
EP (1) EP2504359B1 (enExample)
JP (1) JP2013511966A (enExample)
AU (1) AU2010323144B2 (enExample)
CA (1) CA2782016C (enExample)
DE (1) DE102009047243A1 (enExample)
DK (1) DK2504359T3 (enExample)
WO (1) WO2011064257A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US20170023576A1 (en) * 2014-04-04 2017-01-26 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
CN109641949B (zh) * 2016-08-26 2023-09-15 赛诺菲 促进选择性轻链配对的多特异性抗体
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
WO2020146423A1 (en) * 2019-01-07 2020-07-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
EP4582442A3 (en) 2019-06-24 2025-10-29 Universität Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
JP2000516452A (ja) * 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6151296A (en) 1997-06-19 2000-11-21 Qualcomm Incorporated Bit interleaving for orthogonal frequency division multiplexing in the transmission of digital signals
WO2000075333A1 (en) 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
EP1757622B1 (en) * 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
JP5102772B2 (ja) * 2005-11-29 2012-12-19 ザ・ユニバーシティ・オブ・シドニー デミボディ：二量体化活性化治療剤
EP1954187A1 (en) 2005-12-01 2008-08-13 Atcor Medical Pty Ltd A method of estimating pulse wave velocity
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
US20080260738A1 (en) * 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
EP2139800A1 (en) * 2007-04-20 2010-01-06 Invista Technologies S.à.r.l. Compact continuous over end take-off (oeto) creel with tension control
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien

Similar Documents

Publication Publication Date Title
JP2013511966A5 (enExample)
Rich et al. Survey of the year 2007 commercial optical biosensor literature
ES2637667T3 (es) Un anticuerpo que se une específicamente al factor de crecimiento insulinoide 1
EP3670534A3 (en) Human fgf receptor and beta-klotho binding proteins
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
KR20160014010A (ko) 신규 항체
ES2643640T3 (es) Agentes para tratamiento de enfermedad
BRPI0607315A2 (pt) polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma
AR077088A1 (es) Proteinas biespecificas de union a antigeno
EA201490262A1 (ru) Модифицированные белки и пептиды
DK2504359T3 (da) Monospecifikke polypeptidreagenser
RU2012143798A (ru) Биспецифические антитела
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
Macpherson et al. Isolation of antigen-specific, disulphide-rich knob domain peptides from bovine antibodies
CN109661235B (zh) 抗原结合分子及其使用的方法
CN102245767A (zh) 人cxcl1蛋白质的免疫学测定方法
Nilvebrant et al. Selection and in vitro characterization of human CD44v6‐binding antibody fragments
CA3111050A1 (en) Highly versatile method for granting new binding specificity to antibody
CA3104274A1 (en) Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
Miura et al. Nucleotide-dependent behavior of single molecules of cytoplasmic dynein on microtubules in vitro
JPWO2019244934A1 (ja) 新規抗ｐａｄ２抗体
CN105593241A (zh) 特异性结合her3的抗体
TWI593967B (zh) 二級抗體所辨識之抗原決定位及其用途